Home › Funds › Venrock Adviser, LLC › CTMX
Venrock Adviser, LLC position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
Venrock Adviser, LLC reported holding 4,982,124 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q2 2026 13F filing — a position valued at US$18.7M, representing 0.57% of its reported portfolio and ranking #25 among its reported holdings. Venrock Adviser, LLC has disclosed CTMX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's CTMX position evolved
Venrock Adviser, LLC first disclosed a stake in CTMX in Q2 2025 at 13,969,882 shares (US$31.7M). The position peaked in Q4 2025 at 15,561,500 shares, worth US$66.3M. Across 5 filings, Venrock Adviser, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,982,124 shares valued at US$18.7M — a reduction of -5,000,000 shares quarter over quarter.. Notable position changes include a 36% trim in Q1 2026 (shares fell 20% over the following quarter), a 50% trim in Q2 2026 (shares fell 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 13.97M | $31.71M | New |
| Q3 2025 | 15.56M | $49.64M | Add |
| Q4 2025 | 15.56M | $66.29M | Hold |
| Q1 2026 | 9.98M | $46.92M | Reduce |
| Q2 2026 | 4.98M | $18.68M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 45 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Elmind Capital, LP (US$17.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- Kynam Capital Management, LP 21.70M sh · $81.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Elmind Capital, LP 4.55M sh · $17.06M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- Eversept Partners, LP 3.56M sh · $13.34M · Q2 2026
- ADAR1 Capital Management, LLC 3.37M sh · $12.62M · Q2 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held CTMX?
Venrock Adviser, LLC has disclosed CTMX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Venrock Adviser, LLC's current position in CTMX?
As of Q2 2026, Venrock Adviser, LLC holds 4.98M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $18.68M, representing 0.57% of its reported portfolio and ranking #25.
Has Venrock Adviser, LLC been buying or selling CTMX?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC reduced its position in CTMX. The position peaked in Q4 2025 at 15.56M shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Elmind Capital, LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.